Timely primary percutaneous coronary intervention (PPCI) cannot be offered to all patients with ST-segment-elevation myocardial infarction (STEMI). Pharmaco-invasive (PhI) strategy has been proposed as a valuable alternative for eligible patients with STEMI. We conducted a randomized study to compare the efficacy and safety of a PhI strategy with half-dose fibrinolytic regimen versus PPCI in patients with STEMI.
P
rimary percutaneous coronary intervention (PPCI) is considered to be the best reperfusion option in ST-segment-elevation myocardial infarction (STE-MI) when it can be performed in a timely fashion and by an expert team 1, 2 However, PPCI is not universally available, and delays in performing PPCI are common in real-world practice. 1 Even in some large cities, patients have a high chance of presenting to hospitals not providing around-the-clock PPCI service.
Pharmaco-invasive (PhI) strategy, an early reperfusion strategy encompassing initial prompt fibrinolysis with subsequent early catheterization, has been proposed as a therapeutic option for STEMI patients when timely PPCI is not feasible. 1, 3, 4 However, current evidence on the efficacy and safety of a PhI strategy in patients with STEMI remains limited, and its role is a matter of debate. 5 The recent STREAM trial (Strategic Reperfusion Early After Myocardial Infarction) showed that a PhI strategy could be a reasonable alternative to PPCI in STEMI patients presenting ≤3 hours of symptom onset and with an expected time delay from first-medicalcontact (FMC) to PPCI >1 hour. 6 The only downside of the PhI arm was that its rate of intracranial hemorrhage with full-dose tenecteplase was 5 times higher than that of the PPCI group. However, the difference was not significant after a trial protocol amendment reducing tenecteplase dose by 50% in the elderly. 6 The latter observation suggested that a half-dose fibrinolytic regimen might be a safe and effective option for PhI treatment in eligible patients with STEMI. Interestingly, in an observational registry study in the United States in patients with STEMI with long PCI-related delays, a PhI strategy utilizing half-dose fibrinolysis (97% tenecteplase, 3% reteplase) combined with transfer for PCI achieved similar efficacy outcomes as PPCI without increased bleeding risk. 7 Consistent with these findings, in our pilot study in the Chinese population, early routine PCI after half-dose alteplase fibrinolysis appeared promising in the treatment of patients with STEMI who could not undergo timely PPCI. 8 Because no randomized clinical trials compared the efficacy and safety of a PhI strategy with reduced-dose fibrinolytic regimen versus PPCI in patients with STEMI, we designed the EARLY-MYO trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute STSegment-Elevation Myocardial Infarction) to evaluate the efficacy and safety of a PhI strategy with half-dose alteplase versus routine PPCI in patients with STEMI presenting ≤6 hours after symptom onset and with an expected PCI-related delay.
METHODS

Trial Oversight
The EARLY-MYO was a prospective, multicenter, randomized, parallel-group, open-label, noninferiority trial comparing a PhI strategy with half-dose fibrinolysis versus PPCI in patients with STEMI presenting ≤6 hours after symptom onset and with an expected PCI-related delay of ≥60 minutes (the study protocol is available in the online-only Data Supplement).
The EARLY-MYO investigators conceived, designed, and conducted the trial. They received funding and study drug from Boehringer Ingelheim. Data management and statistical analysis were performed by a third party independent from Boehringer Ingelheim. The first and last authors had full access to the study data, wrote the first draft of the manuscript, and had full responsibility for the decision to submit the report for publication. Boehringer Ingelheim had no role in the design, conduct, analysis, interpretation of data, or reporting of the EARLY-MYO trial. The study was performed in accordance with the Declaration of Helsinki of Good Clinical Practice. The study protocol was approved by an institutional review committee at each clinical center, and all subjects gave informed consent prior to randomization.
Enrollment Criteria
The study enrolled patients between 18 and 75 years of age who presented ≤6 hours after the onset of symptoms with
Clinical Perspective
What Is New?
• The EARLY-MYO trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction) is the first randomized trial comparing the efficacy and safety of a pharmaco-invasive strategy with half-dose fibrinolytic regimen versus primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction. • In low-risk patients with ST-segment-elevation myocardial infarction presenting ≤6 hours after symptom onset and with an expected PCI-related delay, a pharmaco-invasive strategy with halfdose alteplase is noninferior (and even superior) to primary percutaneous coronary intervention for incidence of complete epicardial and myocardial reperfusion.
• Infarct size, left ventricular function, and 30-day clinical outcomes were similar, with minor bleeding seen more often in the pharmaco-invasive group versus the primary percutaneous coronary intervention group.
What Are the Clinical Implications?
• The results of our study suggest that a pharmacoinvasive approach with reduced-dose alteplase seems to offer effective and safe reperfusion in lowrisk patients with ST-segment-elevation myocardial infarction with an expected PCI-related delay.
• Further larger randomized trials are necessary to draw secure conclusions, especially considering that the present study was not powered to assess clinical end points.
specific electrocardiographic criteria for acute STEMI (≥2 mm in 2 contiguous precordial leads or ≥1 mm in 2 peripheral leads) and with an expected PCI-related delay (expected time delay from FMC to first balloon dilation ≥90 minutes and difference between the time of FMC to balloon dilation minus the time from FMC to start of fibrinolysis ≥60 minutes). Key exclusion criteria were any contraindication for fibrinolysis, left bundle-branch block in the presenting electrocardiogram (ECG), cardiogenic shock, and PCI or bypass surgery within the previous month. A complete list of the exclusion criteria is available in the online-only Data Supplement.
Randomization and Treatment
Patients who satisfied the inclusion and exclusion criteria were randomly assigned in a 1:1 fashion to either a PhI strategy with half-dose alteplase (PhI group) or routine PCI (PPCI group), using an interactive web-based response system with a permuted block randomization scheme stratified by time to randomization (<3 hours versus 3-6 hours).
All patients received 300 mg of aspirin and a loading dose of adenosine diphosphate receptor antagonists (300-600 mg clopidogrel or 180 mg ticagrelor) in the emergency room. Patients who had already taken aspirin or adenosine diphosphate receptor antagonists ≤12 hours before screening were given these agents the following day. Patients randomly assigned to the PhI group received half-dose alteplase (8-mg bolus followed by 42 mg in 90 minutes) and an unfractionated heparin bolus (60 U/kg to ≤4000 U followed by 12 U/kg/h to ≤1000 U/h). Eighteen-lead ECG was repeated every 30 minutes after start of fibrinolysis. Patients with persistent ST-segment elevation (ie, <50% resolution of ST-segment elevation) 90 minutes after start of alteplase with or without chest pain were considered as fibrinolysis failures and were referred for immediate rescue PCI. Other patients were recommended to undergo early routine catheterization within 3 to 24 hours after fibrinolysis and further undergo PCI of the presumed culprit lesion if the residual stenosis was ≥50%. Patients randomly assigned to PPCI received unfractionated heparin to achieve an activated clotting time of 350 to 450 seconds during the invasive procedure. PPCI was performed according to standard practice. Stents were implanted whenever technically possible, and the use of drugeluting stents was encouraged. Glycoprotein IIb/IIIa inhibitor use was not allowed in any patient before PCI but was permitted during or after catheterization at the investigator's discretion. The decision to use thrombus aspiration also was at the discretion of the interventional cardiologist. Beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers, statins, and postinterventional antithrombotic therapy were given to all patients as recommended in current guidelines. 3, 4 All study participants were scheduled for follow-up at 30 days after enrollment.
End Points and Definitions
The primary end point of the study was complete epicardial and myocardial reperfusion after PCI, defined as thrombolysis in myocardial infarction (TIMI) flow grade (TFG) 3 for epicardial reperfusion and TIMI myocardial perfusion (TMPG) grade 3 for myocardial reperfusion and complete (≥70%) ST-segment resolution of the initial sum of ST-segment elevation (STR) 60 minutes after PCI.
The key secondary end points were frequency of the individual components of the primary end point: TFG 3 for complete epicardial perfusion, TMPG 3 for complete myocardial perfusion, and STR ≥70% at 60 minutes after PCI. Other secondary end points included: left ventricular (LV) function and infarct size assessed by cardiac magnetic resonance (CMR) on days 4 to 7, wall motion score index assessment by echocardiography on days 4 to 7 and 30 days, and clinical events through day 30.
The key safety end point was the incidence of major bleeding and intracranial hemorrhage.
Epicardial and Myocardial Reperfusion
Coronary angiograms were anonymized and centrally assessed at an independent core laboratory by experienced readers without knowledge of treatment assignment or clinical outcomes. Flow in the epicardial arteries was assessed for TFG and corrected TIMI frame count using previously described methods.
9,10 TMPG and TIMI myocardial perfusion frame count were used to assess myocardial tissue level perfusion.
11,12 TIMI myocardial perfusion frame count is a novel method recently described by our group to standardize and quantify myocardial perfusion. 12, 13 Additional assessment of myocardial reperfusion was carried out using ST-segment analysis. Eighteen-lead ECGs were obtained on admission and 60 minutes after the procedure. At an independent core laboratory, the sum of ST-segment elevation 20 ms after the J point was measured and compared with the baseline ECG. The percent resolution was categorized based on Schroder's method as complete (≥70%), partial (30% to <70%), or none (<30%).
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LV Function
Contrast-enhanced CMR was performed using a 1.5-T, or 3-T scanner using dedicated cardiac surface coils. 15 Infarct size was expressed as a percentage of the LV mass (% LV). The incidence of microvascular obstruction and intramyocardial hemorrhage also were recorded. The scans were reviewed by 2 expert observers at an independent core laboratory. Echocardiography examination was done in hospital on the same day as magnetic resonance imaging examination and at 30-day follow-up. Quantitative echocardiographic analysis of wall motion score index was assessed by the 16-segment model as recommended. 16 All echocardiographic data were stored digitally in digital imaging and communications in medicine format for subsequent offline analysis. Observers of CMR and echocardiography were blinded to the treatment strategy and all other clinical data.
Clinical and Safety Outcomes
Clinical follow-up was performed at 30 days. All-cause death, nonfatal reinfarction, heart failure, and stroke after randomization constituted the clinical end points. The main safety end point was the incidence of major bleeding and other adverse events. All bleeding complications were classified using GUSTO severity criteria (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries). 17 Independent study monitors reviewed all source documents onsite for accuracy and completeness. Clinical and safety end points were verified by a blinded adjudication committee.
Sample Size and Statistical Analysis
The sample size was estimated assuming that the incidence of the primary end point (complete epicardial and myocardial reperfusion after PCI) in the PhI group was 25% and 20% in the PPCI group based on data from the GRACIA-2 trial (Groupo de Análisis de Cardiopatía Isquémica Aguda) and our pilot study. 8, 18 With this assumption, the trial was designed to enter 326 patients to conclude the noninferiority of PhI to PPCI at a 1-sided α=0.025 level based on the prespecified noninferiority margin of 0.7 with 80% power. Assuming a 7% withdrawal rate, a total patient number of 350 (ie, 175 patients per arm) would be needed.
Final Analysis
The primary analysis was performed on the full analysis set on an intention-to-treat basis. The data are presented as numbers and percentages for categorical variables, which were compared using the Fisher exact test; continuous variables are reported as mean±SD or medians with interquartile ranges and were compared using a Student's t test or the Wilcoxon rank sum test as appropriate. The Shapiro-Wilk test was used to examine normality of distribution. The analysis for the primary end point was conducted using the Cochran-MantelHaenszel test controlling for stratification factor (ie, time interval between disease onset and enrollment). The relative risk and its 95% confidence limit were estimated for the primary end point to test for noninferiority between PhI and PPCI. PhI would be claimed as noninferior if the lower bound of the 95% confidence limit lied entirely to the right of the noninferiority margin (δ),which was set as 0.7. If a noninferiority claim was established, then the superiority test would be performed. For the primary end point, we also performed prespecified subgroup analyses according to time to randomization, sex, weight, systolic blood pressure, infarct location, Killip class, and a history of diabetes mellitus or hypertension. For event-free survival, we compared Kaplan-Meier curves using a log-rank test. A 2-sided alpha level of 0.05 was considered to indicate statistical significance. All data analyses were conducted using SAS software (SAS Institute), version 9.2 or higher.
RESULTS
Patients Characteristics
A flowchart of the trial is shown in Figure 1 . A total of 344 patients with STEMI were enrolled from January 13, 2014, to September 25, 2016 , at 7 Chinese centers: 171 were allocated to a PhI strategy and 173 to PPCI. The primary end point (ie, full reperfusion after PCI) could not be calculated in 16 patients (10 in PhI group and 6 in PPCI group; P=0.200). Of the 16 patients with a missing primary end point, 1 died before catheterization could be performed, 3 refused coronary angiography, 1 refused PCI, and 11 did not require PCI. Thus, the primary end point was available in 328 patients (161 in the PhI group and 167 in the PPCI group).
Baseline demographic and clinical characteristics were well balanced and are summarized in Table 1 . The median age of the study population was 58 (interquartile range [IQR]: 51.0-64.0) years, and 88.9% were men. In all, 51.1% had hypertension, 24.4% had diabetes mellitus, and 40.1% presented with an anterior STEMI. The 2 groups had a similar hemodynamic status, depicted by blood pressure, heart rate, and Killip class.
Angiographic data are shown in Table 2 . Distribution of the culprit artery and stent use was similar in both groups. A high rate of radial access was observed in both the PhI (98.1%) and PPCI (97.6%) groups. However, the thrombus burden at first angiography in PPCI group was significantly higher than in the PhI group (P=0.008). Thrombus aspiration (P<0.001) and use of glycoprotein IIb/IIIa inhibitors (P<0.001) were more frequent in the PPCI group. In the PhI group, 120 (74.5%) patients achieved ECG criteria of successful fibrinolytic reperfusion (ie, STR ≥50%) and underwent early routine catheterization. Of these patients, 104 (64.6%) showed TFG 2/3 of the infarct vessel on initial angiography. Forty-one patients (25.5%) were considered as fibrinolysis failures CRP indicates C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PhI, pharmaco-invasive; PPCI, primary percutaneous coronary intervention; SCr, serum creatinine; and TIMI, thrombolysis in myocardial infarction. Data are presented as median (interquartile range), n (%), or mean±SD.
(ie, STR <50%) and underwent urgent angiography. Of these patients, 17 (10.6%) showed TFG 2/3 of the infarct vessel on initial angiography.
A detailed breakdown of time intervals is shown in Table 3 . Symptom onset to FMC and randomization intervals was similar between the 2 groups. The median time between symptom onset and start of reperfusion therapy (alteplase injection or arterial sheath insertion) was 210 (IQR: 166-270) minutes and 280 (IQR: 214-340) minutes, respectively (P<0.001). The median time from randomization to PCI was longer in the fibrinolysis group than in the PPCI group, with a delay of 2.1 hours for rescue PCI and 10.2 hours for routine early PCI.
Epicardial and Myocardial Reperfusion
The primary end point (full reperfusion, defined as TFG 3 and TMPG 3, and complete STR; the patient had to meet all 3 criteria to achieve the primary end point) amounted to 34.2% in the PhI arm versus 22.8% in (Figure 2) . No significant differences by study treatment were found in the frequency of the individual components of the primary end point (Figure 3) , namely, TFG 3 after PCI (91.3% versus 89.2%, P=0.580), TMPG 3 (65.8% versus 62.9%, P=0.730), and STR ≥70% (50.9% versus 45.5%, P=0.377). Consistent with the latter findings, corrected TIMI frame count (as a continuous measurement for epicardial reperfusion) and TIMI myocardial perfusion frame count (as a continuous measurement for myocardial reperfusion) after PCI showed no significant difference between the 2 treatments (Figure 4 ).
Infarct Size and LV Function
CMR was performed at the hospital at a median of 5 (IQR: 4-7) days, with 5.5 (IQR: 4-7) days in the PhI group and 5 (IQR: [4] [5] [6] Figure 5E and F). Analysis of plasma B-type natriuretic peptide level agreed with these findings, with no significant difference between groups in-hospital (P=0.236) and at 30-day (P=0.545) follow-up ( Figure 5G and H).
Clinical and Safety Outcomes
No difference in outcomes was apparent for the rate of major clinical events over the 30-day follow-up (Table 4). In the 3 patients who died, 1 (0.6%) in the PhI group and 2 (1.2%) in the PPCI group, death was secondary to cardiovascular causes (1 cardiac rupture in PhI group, and 1 cardiac rupture and 1 subacute stent PhI would be claimed as noninferior if the lower bound of the 95% confidence limit lied entirely to the right of the noninferiority margin (δ) that was set as 0.7 (indicated as red dash line). PhI indicates pharmaco-invasive; and PPCI, primary percutaneous coronary intervention. thrombosis in the PPCI group). The incidences of nonfatal reinfarction (0.6% versus 0.6%, P=1.0), heart failure (13.5% versus 16.2%, P=0.545), and stroke (0% versus 0%) were similar between groups. The 30-day incidence of the combined outcomes was also similar: 14.6% in the PhI group and 17.9% in the PPCI group, respectively (P=0.466). Kaplan-Meier 30-day eventfree survival curves comparing PhI-treated patients and PPCI-treated patients are shown in Figure 6 (P=0.313 by log-rank test).
The safety outcomes at 30-day follow-up are shown in Table 4 . Rates of major bleeding events (0.6% versus 0%, P=0.497) and intracranial hemorrhage (0% versus 0%) were similar, but minor bleedings were observed more often in the PhI group compared with the PPCI group (26.9% versus 11.0%, respectively; P<0.001). Bleeding events classified by location are shown in Table 5 .
DISCUSSION
EARLY-MYO was the first randomized clinical trial to compare the efficacy and safety of a PhI strategy with half-dose alteplase fibrinolysis versus PPCI in patients with STEMI. The EARLY-MYO results showed that, in patients with STEMI at low risk presenting ≤6 hours after symptom onset and with an expected PCI-related delay, a PhI strategy with half-dose alteplase and timely PCI was noninferior (and even superior) to PPCI in terms of incidence of complete epicardial and myocardial reperfusion. CMR-defined infarct size and LV function as well as the 30-day rate of clinical outcomes were similar. Rates of major bleeding events were similar, and no intracranial hemorrhages were observed in either group, with minor bleedings seen more often in the PhI group.
Reperfusion for STEMI treatment in the modern era encompasses mechanical and pharmacological strategies.
1,2 It is generally well accepted that PPCI is the preferred reperfusion strategy for all patients with STEMI when it can be performed within the guideline-recommended timeframe at PPCI-capable facilities. 3, 4 However, PPCI is not universally available, and large international registries continue to demonstrate persistent delays to PPCI in STEMI. 1 Thus, despite major efforts to develop STEMI networks in many counties, timely PPCI is still limited by challenges in distance, weather, and resources, and physicians are often faced with the decision to either accept PCI-related delays or administer fibrinolysis immediately. 1 It has been suggested that the combination of early reperfusion by initial fibrinolysis with subsequent early PCI, the so-called PhI strategy, could combine the widely available and rapid pharmacological reperfusion with the more complete and sustained reperfusion provided by PCI. Although PhI strategy has been proposed as a therapeutic option for patients with STEMI, current data on the safety and efficacy of such a PhI strategy compared with PPCI are limited. 6, [18] [19] [20] The recent STREAM trial enrolled patients with STE-MI presenting ≤3 hours of symptom onset with an expected time delay from FMC to PPCI >1 hour. The trial showed no significant between-group difference in the primary end point of all-cause death, shock, congestive heart failure, or reinfarction at 30-day and 1-year follow-up. 6, 21 Our EARLY-MYO trial enrolled patients with STEMI presenting ≤6 hours after symptom onset and for whom the expected PCI-related delay was ≥60 minutes. This trial compared the efficacy and safety of a PhI strategy with half-dose fibrinolytic regimen versus PPCI in patients with STEMI. The results showed that a PhI strategy with half-dose alteplase offered more complete epicardial and myocardial reperfusion after PCI when compared with PPCI. Moreover, CMRdefined infarct size and LV ejection fraction were comparable between PhI and PPCI strategies. Using echocardiography, the GRACIA-2 trial showed that 6-week LV ejection fraction was similar between PhI and PPCI groups (P=0.11), 18 whereas by left ventriculograms, the FAST-MI (French Registry on Acute ST-Elevation Myocardial Infarction) showed that in-hospital LV ejection fraction was significantly higher in the PhI arm than in the PPCI arm (P=0.003). 20 At 30-day follow-up, the rate of clinical outcomes including death, nonfatal reinfarction, heart failure, and stroke were equally distributed across the PhI and PPCI groups. Our results are of clinical importance because a PhI strategy with half-dose alteplase fibrinolytic regimen (8-mg bolus, followed by 42 mg in 90 minutes) achieved a reasonable rate of successful fibrinolysis: 74.5% based on clinical criteria (ie, STR ≥ 50% on ECG) and 75.2% based on angiographic criteria (ie, TFG 2/3 on angiography). Although 100 mg alteplase is recommended in a standard or an accelerated regimen in the guidelines, the TUCC trial (TPA/Urokinase Comparisons in China) showed that half-dose alteplase also is effective, with 79% patients achieving a TFG 2/3 on initial angiography after fibrinolysis. 22 Moreover, our pilot study showed that a PhI strategy with half-dose alteplase fibrinolytic regimen achieved 8 Thus, the PhI strategy with half-dose alteplase fibrinolytic regimen appears to be an effective reperfusion strategy for eligible patients with STEMI.
In terms of safety, our study somewhat unexpectedly showed that no intracranial hemorrhages were observed in both the PhI (0 of 171 patients, 0%) and PPCI (0 of 173 patients, 0%) groups at the 30-day follow-up. Note that in the STREAM trial, 6 ,21 the overall rate of intracranial hemorrhage was significantly higher in the PhI versus PPCI group (0.96% versus 0.21%, respectively; P=0.04), but it was not significantly different after the trial protocol was amended to reduce the dose of tenecteplase by 50% (which was made after 20% of planned recruitment) in patients ≥75 years of age (0.54% versus 0.26%, respectively; P=0.45). After fibrinolytic dosage amendment, no cases of intracranial hemorrhage occurred (0 of 97 patients, 0%) among patients 75 years of age or older, compared with 3 of 37 patients (8.1%) in this age group before the amendment, suggesting that a half-dose fibrinolytic regimen in the elderly might reduce bleeding risk in the PhI therapy setting. Also considering the higher bleeding rate (5.0% versus 2.7%, P=0.03) reported by Henry 23 in patients who received full-dose lytics and early PCI, a half-dose fibrinolysis regimen was used in the present study. We observed low rates of major bleeding events in the PhI arm, suggesting that a halfdose fibrinolytic regimen could be an effective and a safe option for PhI therapy in eligible patients with STEMI. It should be noted that our enrolled patients were a lowrisk group (ie, ≈75% had a low TIMI risk score of 0-3, patients >75 years of age were excluded, and >90% of the patients were in Killip class I), which could explain the low event rates observed in our study. Moreover, radial access has recently been associated with a 33% reduction in major bleeding, which drove a 28% reduction of mortality compared with femoral access. 24 Thus, a high rate of radial access (>97%) also would contribute to the low event rate observed in our study. Our CMR findings on intramyocardial hemorrhage were also interesting because one might posit that fibrinolytic therapy would increase the risk of intramyocardial hemorrhage in patients with STEMI. However, the incidence of intramyocardial hemorrhage was comparable between the 2 groups (52% in the PhI arm and 56% in the PPCI arm), indicating that the PhI strategy with a half-dose fibrinolytic regimen would not increase intramyocardial hemorrhage in STEMI. Consistent with our study, the registry investigation by Larson et al 7 in patients with STEMI with expected PCI-related delays showed that a strategy utilizing half-dose fibrinolysis combined with transfer for PCI achieved comparable efficacy outcomes as PPCI without increased bleeding risk.
Another important factor that influenced the efficacy and safety of the PhI strategy is the time window between fibrinolysis and angioplasty. In the ASSENT-4 trial (The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction), 25 patients who underwent PCI at 1 to 3 hours from randomization had higher rates of ischemic complications and mortality than patients undergoing PPCI, which indicates a prothrombotic effect of fibrinolysis followed by too early PCI. In the BRAVE trial (Bavarian Reperfusion Alternatives Evaluation), 26 the fibrinolytic group underwent PCI 2 hours after administration of half- Figure 6 . Kaplan-Meier analysis of freedom from the combined clinical outcomes. Kaplan-Meier survival curve for freedom from the composite of all-cause mortality, nonfatal myocardial infarction, heart failure, and stroke ≤30 days. PhI indicates pharmaco-invasive; and PPCI, primary percutaneous coronary intervention. dose of reteplase instead of a full-dose of fibrinolysis. Despite the higher percentage of preintervention TIMI 3, such an adjustment did not lead to a reduction in infarct size or a better outcome. In our EARLY-MYO trial, the time delay between fibrinolysis and PCI was in accordance with guideline recommendation (within 3-24 hours after fibrinolysis) and similar to the strategies that appeared favorable in the STREAM trial, the GRACIA-2 trial, and the Transfer-AMI trial (Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction).
6,18,27
Limitations
Several study limitations should be considered to place its findings in the proper context. First, the objective of this noninferiority trial was to evaluate the complete epicardial and myocardial reperfusion rate with 2 reperfusion strategies (PhI versus PPCI) aligned with current guidelines in patients with STEMI ≤6 hours and for whom immediate PCI was not possible. More clinical outcome data must be obtained to confirm the reperfusion benefit observed in this study. Second, the reperfusion drugs used in previous studies were tenecteplase or reteplase, which have slower plasma clearance and greater fibrin specificity and can be injected as a bolus. 7 However, alteplase is the only human tissue plasminogen activator available in China during the enrollment period. Third, the patients with STEMI enrolled in the present study were at low risk and not >75 years of age. Thus, the high rate of successful fibrinolysis with half-dose alteplase might not be applicable to all populations and needs to be tested further. Fourth, within the PhI strategy, the optimal timing for routine early PCI after fibrinolysis remains ill defined. Further studies are warranted to identify the best timing for routine PCI after fibrinolysis. Finally, caution is advised when extrapolating our findings to all patients with STEMI within the recommended time window for reperfusion. We should note that in our study, PhI therapy was only considered in patients with STEMI who had expected PCI-related time delay ≥1 hour and only included patients with STEMI presenting ≤6 hours of symptom onset.
CONCLUSIONS
For patients with STEMI at low risk presenting ≤6 hours after symptom onset and for whom the expected PCIrelated delay was ≥60 minutes, a PhI strategy with halfdose alteplase and timely PCI offered more complete epicardial and myocardial reperfusion when compared with PPCI. Particularly relevant to emerging countries with limited health budgets and not well-organized STEMI networks for PPCI, the results of our study suggest PhI therapy as a viable strategy for patients with STEMI who cannot receive timely PPCI. Moreover, the present results also underscore the importance of conducting clinical trials that are adequately powered to assess clinical outcomes and comparative bleeding risks and to optimize treatment strategy for patients at different risk levels.
